-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Enhancing the body's own immune pathways against disease may provide answers to the urgent search for new treatments for tuberculosis
Tuberculosis is still a huge global disease burden and one of the top ten causes of death in the world
The research was led by Dr.
Researchers were able to prove that cells infected with tuberculosis bacteria have a functional apoptotic cell death pathway and showed their importance in fighting serious diseases
Using preclinical models, researchers were able to identify key apoptotic pathways as targets for new therapies, through which drugs called IAP inhibitors can kill infected cells
The study shows that host-directed therapy is feasible for infections such as tuberculosis, which is very important in the era of widespread antibiotic resistance
Fighting antibiotic resistance
Tuberculosis is caused by bacteria that infect the lungs and spreads from person to person through the air
Tuberculosis bacteria grow in the immune cells of the lungs
Using preclinical models, the researchers sequentially deleted key apoptotic effectors to prove their role in controlling tuberculosis infection
Use host-directed therapy to reduce disease burden
Dr.
"When we treated our infection model with this compound, we were able to significantly reduce the number of tuberculosis," he said
"The longer the treatment, the greater the reduction in disease
The research team was able to replicate these results using different IAP inhibitors
"It is exciting that many of these compounds are already in clinical trials for other types of diseases and have been shown to be safe and well tolerated by patients," said Dr.
Stutz
.
"We predict that if these compounds make progress in the treatment of tuberculosis, they will be the most effective if used with existing antibiotic therapies
.
"
Opened the door to new treatments
Professor Mark Pellegrini said that so far, antibiotics are the only way to treat tuberculosis, but due to the increase in antibiotic resistance, the application of antibiotics has been restricted
.
"Unlike antibiotics that directly kill bacteria, IAP inhibitors kill the cells that tuberculosis bacteria need to survive," he said
.
"The beauty of using host-directed therapy is that it does not directly target the microorganisms, but the host process
.
By targeting the host instead of the microorganisms, the chance of drug resistance is very low
.
"
The team hopes that this research will lead to better treatments for tuberculosis
.
"This research increases our understanding of the types of immune responses that benefit us.
This is an important step towards new treatments for tuberculosis.
In the past 40 years, few new treatments have been developed," Dr.
Stutz Say
.
"We have proven that host-directed therapy for infections such as tuberculosis is feasible, which is especially important in the era of widespread antibiotic resistance
.
"